as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Cholinergic urticaria (also called cholinergic angioedema or heat bumps) is a reaction that results in tiny hives surrounded by large patches of red skin. They’re related to an increase in your ...

What is poison ivy rash? Poison ivy rash is an allergic reaction to poison ivy. Poison ivy is very common plant in the U.S. It is similar to two other plants called poison oak and poison sumac. The ...